(Yicai Global) Nov. 25 -- Shares of Sinopharm Group’s listed units jumped after the leading Chinese vaccine producer filed a request to start marketing at least one of its experimental Covid-19 shots in China, which could become the country's first.

China National Medicines [SHA: 600511] soared in Shanghai today by the daily limit of 10 percent to CNY46.43 (USD7.10), while the group’s Hong Kong-listed unit, Sinopharm Holding [HKG: 1099], climbed 5.6 percent to HKD19.74 (USD2.55).

The parent company submitted the sales application request with the National Medical Products Administration, Xinhua Finance News reported today, citing Deputy General Manager Shi Shengyi.

Nearly a million people have received doses of one of the Shanghai-based firm’s two inactivated Covid-19 vaccines via emergency use authorization and they have reported only mild side effects, Chairman Liu Jingzhen told reporters on Nov. 17.

Editor: Emmi Laine